IMMP · Immutep Limited

This Nasdaq bid price deficiency notice reflects a regulatory compliance issue tied solely to the market price performance of Immutep’s American Depositary Shares, not operational or financial deterioration. The notification stems from a sustained sub-$1.00 closing bid price over the 30 consecutive business days ending April 24, 2026 — a mechanical threshold under Nasdaq Listing Rule 5450(a)(1). While the Company retains full trading eligibility on Nasdaq during the 180-day compliance window (through October 26, 2026), failure to meet the $1.00 bid price for ten consecutive business days by that deadline would trigger potential delisting proceedings. Immutep explicitly notes it remains listed and actively traded on the ASX, and this matter does not affect its Australian regulatory standing or share liquidity there. The Company’s statement is procedural and non-committal: it confirms monitoring ADS pricing and evaluating options but discloses no concrete actions — such as a reverse stock split, capital raise, or strategic partnership — nor any timeline or likelihood of resolution. For U.S. investors, this introduces near-term uncertainty around continued Nasdaq quotation and associated liquidity, index eligibility, and institutional ownership constraints — though the absence of any financial, governance, or operational disclosure in the filing limits broader implications.